![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication December 6, 2004.
Revised April 16, 2005.
Accepted for publication April 19, 2005.
Human breast cancer resistance protein (BCRP/ABCG2) is believed to act as an efflux pump to protect the body from drugs and toxins. BCRP is known to accept many kinds of endogenous and exogenous compounds as substrates and to be localized on the apical membrane of various tissues. Expression of BCRP is also reported on the side population cells and a recent report suggested involvement of Akt in the modulation of the side population phenotype. In the present study, we have characterized the effect of Akt on the polarized expression of BCRP using LLC-PK1 cells. After treatment with PI3K inhibitors, internalization of stably-transfected BCRP from the apical surface was observed following immunohistochemical staining and the relative expression level of BCRP on the cell surface decreased to 49 ± 14% and 51 ± 8% of the control for LY294002 and wortmannin treatment, respectively. This phenomenon was supported by the observation of internalized BCRP in presence of DN-Akt. When the cells were treated with EGF, the cell surface expression of BCRP was increased to 228 ± 43% of the control accompanied by Akt stimulation. These results suggest that the relative expression of BCRP on the cell surface is regulated by the PI3K-Akt signaling pathway with a positive correlation in polarized cells. Alteration in Akt activities may influence the cellular extrusion of BCRP substrates by modifying epithelial BCRP localization.
Key words:
ABC transporters, intestinal transport, regulation of gene expression
This article has been cited by other articles:
|
|
 |
|
  N. Yoshida, T. Takada, Y. Yamamura, I. Adachi, H. Suzuki, and J. Kawakami Inhibitory Effects of Terpenoids on Multidrug Resistance-Associated Protein 2- and Breast Cancer Resistance Protein-Mediated Transport Drug Metab. Dispos., July 1, 2008; 36(7): 1206 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Gilg, S. L. Tye, L. B. Tolliver, W. G. Wheeler, R. P. Visconti, J. D. Duncan, F. V. Kostova, L. N. Bolds, B. P. Toole, and B. L. Maria Targeting Hyaluronan Interactions in Malignant Gliomas and Their Drug-Resistant Multipotent Progenitors Clin. Cancer Res., March 15, 2008; 14(6): 1804 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Katayama, S. Yoshioka, S. Tsukahara, J. Mitsuhashi, and Y. Sugimoto Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein Mol. Cancer Ther., July 1, 2007; 6(7): 2092 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakanishi, K. Shiozawa, B. A. Hassel, and D. D. Ross Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression Blood, July 15, 2006; 108(2): 678 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. M. zu Schwabedissen, M. Grube, A. Dreisbach, G. Jedlitschky, K. Meissner, K. Linnemann, C. Fusch, C. A. Ritter, U. Volker, and H. K. Kroemer EPIDERMAL GROWTH FACTOR-MEDIATED ACTIVATION OF THE MAP KINASE CASCADE RESULTS IN ALTERED EXPRESSION AND FUNCTION OF ABCG2 (BCRP) Drug Metab. Dispos., April 1, 2006; 34(4): 524 - 533. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
